Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio1.67
Quick Ratio1.67
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.43 million
Price / Sales4.69
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book2.14
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,140,000.00
Net Margins-120.14%
Return on Equity-176.04%
Return on Assets-97.94%
Miscellaneous
Employees18
Outstanding Shares16,520,000
Market Cap$27.09 million
Soligenix (NASDAQ:SNGX) Frequently Asked Questions
What is Soligenix's stock symbol?
Soligenix trades on the NASDAQ under the ticker symbol "SNGX."
How were Soligenix's earnings last quarter?
Soligenix, Inc. (NASDAQ:SNGX) issued its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.06. The biopharmaceutical company earned $1.70 million during the quarter, compared to analysts' expectations of $1.20 million. Soligenix had a negative net margin of 120.14% and a negative return on equity of 176.04%. View Soligenix's Earnings History.
When is Soligenix's next earnings date?
What price target have analysts set for SNGX?
2 brokerages have issued 1-year target prices for Soligenix's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Soligenix's stock price to reach $3.50 in the next year. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Soligenix.
What is the consensus analysts' recommendation for Soligenix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soligenix.
Who are some of Soligenix's key competitors?
Some companies that are related to Soligenix include Oncomed Pharmaceuticals (OMED), Aerpio Pharmaceuticals (ARPO), Oncolytics Biotech (ONCYF), Northwest Biotherapeutics (NWBO), Leap Therapeutics (LPTX), Aridis Pharmaceuticals (ARDS), Arcturus Therapeutics (ARCT), Vernalis (VNLPY), Vaccinex (VCNX), BIOLINERX Ltd/S (BLRX), XBiotech (XBIT), Evofem Biosciences (EVFM), Scpharmaceuticals (SCPH), GT Biopharma (GTBP) and BELLUS Health (BLUSF).
Who are Soligenix's key executives?
Soligenix's management team includes the folowing people:
- Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 52)
- Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 64)
- Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 46)
- Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 66)
- Mr. Adam T. Rumage, VP of Project Management & Regulatory Affairs
Has Soligenix been receiving favorable news coverage?
Press coverage about SNGX stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Soligenix earned a daily sentiment score of 0.18 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Soligenix.
How do I buy shares of Soligenix?
Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soligenix's stock price today?
One share of SNGX stock can currently be purchased for approximately $1.54.
How big of a company is Soligenix?
Soligenix has a market capitalization of $27.09 million and generates $5.43 million in revenue each year. Soligenix employs 18 workers across the globe.
How can I contact Soligenix?
Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]
MarketBeat Community Rating for Soligenix (NASDAQ SNGX)
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
